PACCE: A Randomized, Open-Label, Controlled, Clinical Trial of Chemotherapy and Bevacizumab With and Without Panitumumab in the First-Line Treatment of Subjects With Metastatic Colorectal Cancer.

Trial Profile

PACCE: A Randomized, Open-Label, Controlled, Clinical Trial of Chemotherapy and Bevacizumab With and Without Panitumumab in the First-Line Treatment of Subjects With Metastatic Colorectal Cancer.

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Jun 2013

At a glance

  • Drugs Panitumumab (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms PACCE
  • Sponsors Amgen
  • Most Recent Events

    • 21 Jan 2011 Status changed from discontinued to completed as reported by ClinicalTrials.gov record.
    • 29 Dec 2008 Results reported online in the Journal of Oncology.
    • 30 Jun 2007 Results of first interim analysis presented at 9th World Congress on Gastrointestinal Cancer 2007.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top